ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 245 entries already.
Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
Early January saw a few indicators that stock markets might deliver some solid biotech results in 2016, even if it wasn’t destined to be a hallmark year for the industry. But then, in the weeks that followed, the situation began to deteriorate. Now it looks like European biotech companies might have to start coming to terms with a closing IPO window.
The Operetta CLS system enables scientists to gain deep biological insight into disease from common assays and complex applications using advanced cellular models, and to identify even subtle phenotypic changes through sensitive imaging and intuitive data analysis.
Art Robbins Instruments has converted – together with the American company SciGene – the Scorpion workstation to automate MicroFISH slide preparation.
The LabChip® GXII Touch System offers researchers an automated alternative to traditional methods by streamlining the multiple, manual steps of slab gel electrophoresis, while also providing the throughput and data quality essential in the biotherapeutics workflow.
Recipharm remains on track for growth. The Swedish CDMO is acquiring Italian injectable beta lactam expert Mitim Srl. The takeover is worth €68.4m.